HOW IS OLEPTRO DOING??


Pharmacies are paying about $2-3/100 tabs of t'done. If they sell 30 under their $4 co-pay program, their profit is still huge. Don't think for a second that pharmacies won't switch it. You've got a huge uphill climb with docs, insurance, & pharmacies. If you have huge sales goals too, wow!
 

How long can this go on like this? Will Q-L reevaluate reality? New to contract and know contract can be cancelled at any time, but with sales so below expectations, can L afford to drop us already or let us settle in and grow our business at this pace?



If sales do not turn around 6 or so months after launch, it will be dropped and ended. Start looking.
 
Start looking immediately. Labopharm (DDSS) has been notified of the ANDA submission by Atavis for the sale of generic Oleptro in the U.S. (November 12th, 2010). What little market share there is will be taken away.
 
I didn't see that anywhere. I did see the info on their website.

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

Under the Drug Price Competition and Patent Term Restoration Act (known as the Hatch-Waxman Act), OLEPTRO™ has a new dosage form market exclusivity period that prevents final approval of Actavis' ANDA until the exclusivity period expires on February 2, 2013.

Activis' ANDA includes a paragraph IV patent certification to obtain approval to manufacture, use, or sell its generic versions before the expiration of Patent No. 6,607,748, which is owned by Labopharm Inc., in June 2020. The patent is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluation (the "Orange Book").

Labopharm is currently reviewing the notice letter to determine next steps in this matter.

Source: LABOPHARM INC.

Bottom line kids, you have 2 years to sell a drug that is older than dirt to make a failing company profitable (labo stocke closed @ .97) Have fun with that!
 
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

Under the Drug Price Competition and Patent Term Restoration Act (known as the Hatch-Waxman Act), OLEPTRO™ has a new dosage form market exclusivity period that prevents final approval of Actavis' ANDA until the exclusivity period expires on February 2, 2013.

Activis' ANDA includes a paragraph IV patent certification to obtain approval to manufacture, use, or sell its generic versions before the expiration of Patent No. 6,607,748, which is owned by Labopharm Inc., in June 2020. The patent is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluation (the "Orange Book").

Labopharm is currently reviewing the notice letter to determine next steps in this matter.

Source: LABOPHARM INC.

Bottom line kids, you have 2 years to sell a drug that is older than dirt to make a failing company profitable (labo stocke closed @ .97) Have fun with that!



So do you think we have 2 years left or do you think it may end earlier? It was supposed to be a 5 year contract.
 
And weekly numbers decreasing not increasing. Rats in the process of abandoning ship.

Weekly numbers decreasing?? I find that hard to believe. It's tough bringing a new AD to market (and even tougher with so many generics available), and takes a good amount of time to gain traction. You've only been out there four months so far. On the other hand, you have some great advantages to talk about with Oleptro! I would have given just about anything to be on this project and really believed Oleptro would have a very successful launch. Maybe I'm crazy, but I still think it will grab a reasonable amount of market share over time.

I don't really expect anyone to respond, but I'd love to hear a (relatively) objective opinion of how Oleptro is being received. How can a doc argue the idea of decreased weight gain, decreased sexual dysfunction, and the probability of a better night's rest in comparison to most other AD options available? Ah well... Hope things start looking up soon, Good luck!
 
Maybe I'm crazy, but I still think it will grab a reasonable amount of market share over time.


I too believe Oleptro will have a decent market share over time, but it will take time, and I am not sure how long AL wants to wait.
 
The regional managers need to better evaluate the DM candidates for ability to travel. 2 DMs left from same district..1st (female lasted 3 weeks) had issues with travel..2nd (male 4 mos.) left on his own to take better position in sales, less travel. If RBM are upfront about travel..
 


Write your reply...